Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

New first-line therapy for HER2-positive metastatic breast cancer shows promising results in clinical trial data.